Diabetes Related Markers - CLIA
Tests for quantitative determination of diabetes related markers in human specimen by microplate enzyme immunoassay, chemiluminescence.
Part #: Refer to the respective IFUs
Manufacturers:
Description
Insulin and C-peptide are produced by the enzymatic cleavage of proinsulin within pancreatic beta cells and are released into the circulation in equimolar amounts. Insulin is the primary hormone responsible for regulating blood glucose levels, while C-peptide serves as a reliable marker of endogenous insulin secretion. In-vitro measurement of insulin and C-peptide levels plays an important role in the diagnosis and management of diabetes mellitus.
Assessment of insulin and C-peptide helps differentiate between type 1 diabetes, type 2 diabetes and other forms of diabetes by evaluating residual beta-cell function. These measurements are useful in assessing insulin deficiency, insulin resistance and pancreatic beta-cell activity. Additionally, insulin and C-peptide testing aids in distinguishing endogenous insulin production from exogenous insulin administration, which is particularly important in the evaluation of hypoglycemia in diabetic patients.
Technical specifications
| Analyte | Principle | Calibrator Concentration | Measurement Range | Assay Time |
| Insulin | Sandwich assay | 0, 5, 25, 50, 100, 300 µIU/mL | 0.114 – 300 µIU/mL | 65 minutes |
| Insulin (VAST kit) | Sandwich assay | 0, 5, 25, 50, 100, 300 µIU/mL | 0.114 – 300 µIU/mL | 75 minutes |
| C-peptide | Sandwich assay | 0, 0.2, 1, 2, 5, 10 ng/mL | 0.012 – 10 ng/mL | 65 minutes |
| C-peptide (VAST kit) | Sandwich assay | 0, 0.2, 1, 2, 5, 10 ng/mL | 0.012 – 10 ng/mL | 75 minutes |
Refer to the product Instruction-For-Use (IFU) for complete details.